High Dimensional Analysis of Immune Cells in Pediatric Patients

Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Apr 19, 2023

Keywords

ClinConnect Summary

This clinical trial is designed to study the immune cells of children aged 2 to 18 years who are undergoing surgery with general anesthesia, specifically those who will receive a medication called Rocuronium, which helps relax the muscles during surgery. The researchers want to understand how these immune cells behave, especially in cases where there might be an allergic reaction to the drug. By analyzing these cells closely, they hope to learn more about how the immune system works in children and improve safety for future surgeries.

To participate, children must be between 2 and 18 years old and scheduled for surgery using Rocuronium. However, those who have certain health conditions, such as autoimmune diseases or those taking specific medications that affect the immune system, are not eligible. If your child qualifies and participates, they will undergo routine procedures as part of their surgery, with no additional treatments or tests beyond what is standard. This study aims to gather important information that could enhance patient care and safety in pediatric surgeries.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Pediatric patients between the ages of 2 and 18 undergoing general anesthesia and surgery using the neuromuscular blocker, rocuronium.
• Exclusion Criteria:
• • Patients who have received immunomodulators, immunosuppressants, etc.
• • Patients with autoimmune diseases (rheumatoid arthritis, lupus, Behcet's disease, etc.)
• • Patients who regularly take, or have taken within 4 weeks, medications that may affect the immune system (oral steroids, anti-inflammatories, etc.)
• • Other cases where the Principal Investigator determines that it is difficult to conduct the study.